NCT04637620RecruitingPhase 2
NMDA Modulation in Major Depressive Disorder
Source: ClinicalTrials.gov · Last updated 23 Oct 2026
Brief summary (registry, in English)
Most of the current antidepressants for major depressive disorder (MDD) are based upon the monoamine hypothesis which cannot fully explain the etiology of depression. NMDA hypofunction has been implicated in the pathophysiology of depression. Therefore, this study will examine the efficacy and safety as well as cognitive function improvement of an NMDA enhancer (NMDAE) in the treatment of MDD in the adults.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- First submitted
- 11 Oct 2020
- Start date
- 1 Jun 2017
- Primary completion date
- Nov 2026
- Lead sponsor
- China Medical University Hospital
- Diseases
- Depression
- NCT number
- NCT04637620
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 90
- From 1 Jun 2017 to the primary completion date, Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Initiating or stopping formal psychotherapy within six weeks prior to enrollment
- A history of previously received electroconvulsive therapy
Other illness
- Current substance abuse or history of substance dependence in the past 6 months
- History of epilepsy, head trauma, stroke or other serious medical or neurological illness which may interfere with the study
- Bipolar depression, schizophrenia or other psychotic disorder
- Severe cognitive impairment
- A history of severe adverse reaction to SSRIs
Other
- Moderate-severe suicidal risks
- A treatment-resistant history (that is, they have failed to respond to two or more different classes of antidepressants with adequate dosage and treatment duration
- Inability to follow protocol
Who the study is looking for
- Have a DSM-5 (American Psychiatric Association) diagnosis of MDD
- 17-item Hamilton Rating Scale for Depression total score ≥ 18
- Free of antidepressant drugs for at least 2 weeks
- Agree to participate in the study and provide informed consent
Age in the registry: 18 years to 55 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Psychiatry, China Medical University Hospital Coordinator of this site? Confirm its status | Taichung | Taiwan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.